Member Info for PM2022

Maybe they are inside doh. Lifetime of bitterness scumbag. Give it time I am sure we will get some big investors.

Great news. 30p and 40p hurdles and SP will have to remain above that level for a decent period of time.

I would be shocked if we do not hit at least 35p/45p before Christmas. The staff will want a bonus in these tough times. Lots of positive news due so expected.

Just someone trying to drag it down to buy cheaper.

Hardly any downside here worth a buy with so much news due.

I expect the confidence will change Fredd when the deal gets done soon with all the follow on news to come. Seen over the years single very early stage lab experiments valued over 100 million like Braveheart was and so many others. We would just reach fair value imo. We were 74p on 201 results now we have a strong base in lots of ways. TNBC will be a blockbuster as well and we will get big investments coming in for that. What an asset.

Great time to invest at these prices.

List of likely RNS coming up before Christmas. Target price 80-100p. 201 Deal would be the huge one that takes us up multiples. Not much downside given all this news to come.

1) TNBC - SPV this week or the next few days
2) VAL 201 funding completed TRX plans
3) 201 Payment of consultancy fees
3) 201 Trial news/plans
4) 201 Patent application likely new 20 year patent
5) New Scientist before Christmas
6) VAL 301 update is very likely before Christmas
7) Outcome of Hakkido University evaluation by 16 dec
8) II investors RNS once 201 completed decent shout
9) Outstanding findings regarding BC201
10) Cash from Cenkos Warrants once 201 deal completed

My view is that 201 is imminent as well because if extension was granted based on evidence a few months back and if Suzy is 100% confident recently then that can only be the case if an agreement in principle has been reached already. TRX has big plans so that is the reason why it's taken long.

We should get confirmation of TNBC today or tom I think given it is already out. 201 to follow shortly I am 100% confident about that.

A 15 Million market cap is too cheap. Given 201 is also progressing well and when the deal is signed surely we should be 50 million plus given we have such a promising preclinical pipeline. Another two that can enter SPV as well if the evaluation is positive and 301 which should take us further in terms of market cap. The only way is up here.

Lots of news due. STRONG BUY.

We are in a period now where lots of news is due so you will probably miss out for the sake of buying in 1p cheaper. We saw another stock rise 150% yesterday so volume is around but the difference is that one is a very long way from the next big news and we in comparison have a very valuable preclinical strategy with news dropping all the time. Also VAL201 is a phase 2b drug and if the patents are sorted we would be worth very big money just on that alone.

By Jan/Feb it is very possible we can have 3 in SPV and the deal for 201 completed. TNBC then we have two more in evaluation which I hear are very promising and 301 as well. Add that with the completed deal for 201 then we are easily looking at 50-100 million market cap in the next three/four months even with 2 in SPV. A deal can be struck anytime when in SPV with a possible 20 million odd upfront and huge milestone payments. We also get more promising drugs over the coming months and I'm sure our new experienced staff will assist in getting some great ones.

I see all this news as a foundation being built. Bit like building a house. So when the 201 deal is done it rises fast but it will also keep most of the value as if it drops it will have buyers due to the potential. So it will not be a spike then a large drop.

RIsk is very low at the moment. Cash for at least a year with 201 completed and Cenkos warrants make it at least two years. Huge upside and I think soon we will never see these prices again.

Not really we should get TNBC news in the next few days or even tomorrow. I don't think 201 is far. It will all add up to a big correction in the SP.

Ideally I would get TNBC news out first before the 201 deal as VAL would seem even more attractive for potential investors investing once the deal is completed.

Never buy on a spike as sometimes it goes down as fast but another company is up 130% today after a similar deal.

Now with VAL being valued at 15p and a market cap of 14 million It is very possible we get a 200-300% rise after the deal at these prices especially if TNBC goes into SPV before.

We are not a single drug company. The market will catch onto our strategy once the deal is done so it's always good to load up earlier. Less chance of being spiked and greater value but bit more risky but I feel 201 deal is not priced here but highly likely to be completed very soon.

Downside from current SP 3-4p IMO if no deal but upside from current sp with preclinical news due anywhere between 20-80p short/mid term therefore 35p to approx 100p with deal plus other news such TNBC in SPV and positive 301 news or positive Hakkaido outcome in SPV.

I will invest a bit here when the price drops as we have a gap of one year here. Still really mainly a one drug company.

For me on AIM watch out for Valirx as 201 should be done soon but it has so much more with an evolving preclinical pipeline which is worth 10s millions once in SPV. The RNS shows investing early is the way forward rather than buying up 80%. Interesting times for biotechs GL all.

No doubt buyers are waiting to jump in at 15p but it's clear from Suzy's responses that TNBC news should be announced one of these days. The price will move fast.

I am sure we will get a news rich period from now as Suzy will want her staff to get the bonus for Christmas from the options. First option hurdles 25p-30p with 20 day VWAP.

Expecting news for TNBC, VAL 201 soon and also 301 before Christmas. Strong buy with huge upside.

Val will go back up just depends what your average is.

Email your concerns to Adam. Everything happens for a reason and lots of disruptive posters here at times.

Worth watching the video at 39 min-42 min. Suzy stated 201 looks much better than a few months ago then directly looks at the camera and smiles and nods her head as to say yes. Strong body language. Also her answer to Nick's question stating lots can happen between now and any future raise and giving reference to 201 and other news.

Anyway we will not know when the news comes but judging from her body language she was saying it is close. It will just land when it does and realistically you would be looking at a rise of over 200% at the current sp. Lots of people doubt the deal and they will buy much higher as we would still be cheap. Always buy early imo.

Basic research should indicate no shareholder would accept that price so they have no chance. They would have to offer at least 50p to even have a chance.

Very good Zoom call. If patents are sorted and announced with the deal or soon after then the value of 201 will be absolutely huge. It looks very much on. If funding was not done this would not be looked at is my understanding but I need to watch the Zoom call again.

When TNBC enters the SPV stage and at some stage we should be able to work out the value that will reflect in the market cap. 301 also has the potential to multibag us alone if good news.

I agree and listen out for 301 as that could be a game changer. It's all relative to our market cap. So in the next 4-6 weeks if we get news on TNBC, 301 and 201 deals plus the new drug candidate we will not be below 35-40p. We have to watch and judge based on the portfolio and potential.

The bottom line and the only thing that matters is are we worth 14 million? Yes or no and what kind of news would be due in the coming months. Whether 201 gets done tomorrow or in 4 weeks does not matter so much as long as it's not another long delay.

Get the word out about the zoom call. A cheap buy for those looking to enter today.

Big week ahead. Finally we might get an RNS for 201 or 301 or at least some update during the Q and A and hopefully positive SP movement this coming week. I look forward to hearing more information regarding our preclinical strategy. For those that have missed the recent RNS below.

Live Q&A: London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, invites shareholders to join the CEO, Suzy Dilly and Shareholder Representative, Adam Hargreaves in a Zoom webinar on 29 September 2022 at 1pm (UK).

Registration prior to the event is recommended to ensure all notifications about the webinar are received by participants. Please register in advance of the event at: https://us02web.zoom.us/webinar/register/WN_LnCNxEbBSMOjzzYMxddhLA.

These registration details will also be available on the ValiRx website (https://www.valirx.com/contact). The format will comprise a "fireside chat" between Dr Dilly and Professor Hargreaves by the Company with shareholders invited to submit their questions prior to the event, or to activate their webcam and speak directly to ask their additional questions during the session. A recording of the event will be available to view from the ValiRx website shortly after the event concludes.

Another sign of confidence to take questions live. Suzy knows 201 will be the popular questions asked at the moment. I don't think she would put herself forward in such a way if she was not confident that the deal is about to be announced. This added to the option hurdles and the fact they have hired a marketing firm should give confidence that the deal is on track to complete now.

The company has fantastic assets with cash for the next 1-2 years. I think 301 could also be as good or better than 201 even at pre-clinical stage with a chance for it to get a deal or be sold soon. This would bring further significant cash whilst new projects come on board.

Decent chance of an RNS for either 201 or 301 next week including the day of the Zoom call. I expect that we will form a new base in the coming days. The coming days will be the last chance to buy at these prices imo.